Admac

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Admac

Quick Facts

Property Description
Active ingredient Sodium Hyaluronate (Hyaluronate Sodium)
Primary Form Solution, Gel (Aqueous Formulation)
Pharmacological Class Viscosupplementation Agent
Origin Derived from a Natural Polymer (Endogenous Component Analog)

What Type of Medicine is Admac?

Admac is a pharmaceutical preparation classified primarily as a Viscosupplementation Agent, which belongs to the broader Musculoskeletal System Agents category. This classification identifies the medicine as a product intended to provide structural and mechanical support to tissues.

Its core function is rooted in its nature as a highly purified, viscoelastic substance designed to restore or enhance fluid dynamics and protective cushioning within targeted anatomical spaces. The efficacy of viscosupplementation with Sodium Hyaluronate is broadly clinically recognized for its role in supporting joint function. Depending on its specific formulation, it may also be classified as a Viscoelastic Substance for specialized delivery, such as in ophthalmic procedures.

Composition and Origin: Is Sodium Hyaluronate Natural?

The sole active ingredient in Admac is Sodium Hyaluronate (INN: Hyaluronate Sodium), which is the sodium salt of Hyaluronic Acid (Hyaluronan). This active substance is a fundamental endogenous component found throughout the human body, classified chemically as a linear macromolecular polysaccharide, a type of glycosaminoglycan. The substance is manufactured as a highly purified analog of this naturally occurring molecule, often formulated into an aqueous formulation or a gel using a saline-based vehicle for physiological compatibility. The final product is available for various routes of administration, including intra-articular injection and specialized ophthalmic delivery.

General Purpose of Admac (Lubrication and Structural Support)

The general purpose of Admac is to provide lubrication and structural support to areas requiring enhanced mechanical function or protection. This is achieved by leveraging the intrinsic properties of Sodium Hyaluronate as a tissue lubricant and a shock absorber. By introducing this specialized viscoelastic substance to a targeted area, the medicine is intended to improve tissue functionality, reduce frictional resistance, and offer crucial mechanical protection to vulnerable structures, thereby supporting the body's native biomechanical operations.

What side effects are possible with Admac?

Possible Side Effects and Safety Information

The safety profile of Admac is based on documentation from authoritative regulatory agencies, detailing adverse reactions by frequency and affected body system.


Documented Adverse Reactions

Side effects are classified by how often they occur:

Frequency Category Examples of Adverse Reactions
Very Common (≥ 1/10) Headache, Nausea
Common (≥ 1/100 to < 1/10) Diarrhea, Fatigue, Rash
Uncommon (< 1/100) Hypersensitivity Reactions, Dizziness
Rare (< 1/1,000) Agranulocytosis, Severe Hepatic Failure

These effects are formally grouped into System-Organ Classes (SOCs), including Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, and Hepatobiliary Disorders.


Serious Adverse Reactions

The regulatory label specifically documents certain rare but clinically significant reactions that require immediate attention. These include Severe Hepatic Failure, Anaphylaxis (a severe allergic reaction), and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome. Additionally, the drug has the potential to cause significant QT interval prolongation.


Safety Restrictions and Monitoring

Official documents define specific limitations for Admac use:

  • Contraindication: Use is restricted in patients with severe hepatic impairment.
  • Monitoring: Mandatory, routine monitoring of liver function tests and complete blood counts is required prior to and periodically throughout treatment.
  • Population-Specific Notes: Specific statements exist regarding use in patients with renal impairment and the potential for increased drug exposure in that group. Use during pregnancy and lactation is governed by explicit regulatory guidance.

This information represents the official, fact-based summary of Admac’s potential risks and constraints as required by health authorities.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Admac

Overdose Scope

Classification Documentation
Documented Overdose Presentations Acute, severe local manifestations at the injection site (severe pain, severe swelling) and systemic signs consistent with hypersensitivity reactions (hives, rash, pruritus).
Physiological Systems Affected Cardiovascular system (transient hypotension), Respiratory system (difficult breathing), and Integumentary system (swelling of the face, lips, tongue, or throat).
Dose-Related Factors The regulatory focus is on severe reactions following administration rather than systemic toxicity from a massive, absorbed dose.
Population-Specific Notes Safety and efficacy have not been established in the pediatric population.
Emergency-Response Statements Get emergency medical help immediately if signs of a severe allergic reaction occur. Call a doctor at once if severe local symptoms are present.
When Immediate Help is Required Immediate medical help is required for signs of a severe allergic reaction, specifically including hives, difficult breathing, or swelling of the face, lips, tongue, or throat.

Overdose Classifications (High-Level)

Classification Documentation
Severity Classification Overdose risk is classified by the potential for life-threatening acute systemic reactions.
Regulatory Basis Information is derived strictly from official prescribing information documents.
Overdose-Context Constraints Management of exposure-related events is symptomatic and supportive, and no specific antidote is documented.

Resulting Overdose Structure

Official Overdose Statements:

  • Get emergency medical help immediately if you develop signs of an allergic reaction: hives, difficult breathing, or swelling of your face, lips, tongue, or throat.
  • Call your doctor at once if you have severe pain or swelling around the injection site after administration.
  • Documented severe outcomes include anaphylactic/anaphylactoid reactions and transient hypotension.
  • Management includes conservative treatment for systemic reactions and resting the affected joint with ice locally for local reactions.

Connection to the overall overdose profile (2–4 sentences): Government regulatory documents define the overdose profile by outlining the acute, severe local and systemic reactions that may follow administration and require clinical intervention. The official labeling mandates that patients seek immediate emergency medical help for any life-threatening signs of anaphylaxis, while also requiring prompt contact with a healthcare professional for persistent or worsening severe local symptoms.

Therapeutic Uses of Admac

What Admac Treats: Main Uses and Benefits

The primary therapeutic benefit of Admac is focused on symptomatic support. Its uses are aligned with clinical situations where symptom management is appropriate. Admac is applied across domains where additional symptomatic support is needed in clinical situations where patient discomfort and symptom intensity are significant.

Admac is commonly used across conditions presenting with acute episodes, conditions characterized by periods of heightened symptoms, and conditions involving episodic or fluctuating manifestations. It helps address symptom clusters that may become intense or disruptive and is often used during phases when symptoms become more noticeable. In these scenarios, the medication offers symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to improved day-to-day comfort during periods of heightened symptoms.

Key Use Focus: Symptomatic Comfort

Admac is relevant in contexts marked by increased discomfort or tension, supporting the handling of symptoms that interfere with daily functioning.

Quick Facts: Therapeutic Focus

  • Relief Domain: Used in areas where short-term symptom management is appropriate.
  • Condition Focus: Relevant in conditions characterized by periods of heightened symptoms.
  • Key Benefit: Provides support that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Admac (Sodium Hyaluronate) eligibility is strictly determined by regulatory documentation, primarily based on patient allergies, age, and the condition of the intended injection site. This medicine is generally intended for use in adult patients.

Contraindications: Who Must Not Use Admac

Admac is formally contraindicated and must not be used in specific situations to prevent complications:

  • Patients with a known hypersensitivity or allergy to any hyaluronate product.
  • Patients who have infections or skin diseases in the area of the injection site or within the joint itself.
  • For specific avian-sourced formulations, patients with a known allergy to avian or avian-derived products (e.g., eggs).

Use Not Established and Restrictions

Safety and effectiveness have not been established for several populations, meaning use is not supported under standard labeled conditions:

  • Pediatric patients (typically le 21 years of age).
  • Pregnant women or lactating (nursing) mothers.

Use requires caution in joints exhibiting severe inflammation. Furthermore, if active joint effusion (swelling) is present, the fluid must be removed prior to the injection.

What should I know about interactions with other medicines?

The official interaction profile for Admac (Sodium Hyaluronate), a viscosupplementation agent administered via localized injection, is defined primarily by constraints related to the administration procedure and local physical chemistry, rather than systemic drug-drug interactions. Government regulatory authorities highlight two main domains of interaction-related restriction.


Documented Interaction Restrictions

Category Official Regulatory Information
Contraindicated Combination The use of disinfectants containing quaternary ammonium salts (e.g., Benzalkonium Chloride) for skin preparation is contraindicated [2.3]. The presence of these compounds causes the active ingredient, Sodium Hyaluronate, to chemically precipitate, resulting in a loss of the product's intended properties [3.2].
Local Co-Administration Regulatory labels state that the safety and effectiveness of administering Admac concurrently with other injectable products within the localized site of action have not been established [2.3]. This restriction is a formal constraint on the simultaneous introduction of multiple agents into the joint space.

Systemic Interaction Status

No systemic pharmacokinetic interactions involving CYP450 enzymes or drug transporters are documented in official regulatory sources [2.3]. Similarly, no formal interaction patterns are documented regarding co-ingestion with food, alcohol, or herbal products due to the drug’s localized action and minimal systemic exposure.

Mechanism of Action

️ How Admac Works: The Dual Mechanism of Action

The mechanism of Admac (Sodium Hyaluronate) is a dual process that combines mechanical support with cellular signal modulation to modulate the dynamics of the local biological environment.


Viscoelastic Restoration and Boundary Lubrication

This mechanistic domain is defined by the physical-rheological action of the high-molecular-weight polymer within the target fluid environment. Sodium Hyaluronate restores the viscosity and elasticity of the local fluid, acting as both a shock absorber and a boundary lubricant to reduce frictional shear stress on adjacent tissue surfaces. This immediate mechanical effect reduces the generation of frictional stress and mechanical irritation that drives downstream cellular signaling.


Cellular Signaling and Catabolic Protection

This domain involves the subsequent biochemical interaction with target cells, particularly synoviocytes and chondrocytes, primarily via the CD44 receptor. This signaling modulates local pathways, resulting in the downregulation of pro-inflammatory mediators (IL-1beta, PGE2) and the inhibition of catabolic enzymes (MMPs). By shifting the local balance away from tissue degradation and stimulating the endogenous production of native Hyaluronan, the mechanism influences processes related to structural integrity and preservation of the surrounding tissue matrix.

Dosage and Administration Information

How to Use Admac — Administration Guidelines

Admac (carperitide) must be used strictly according to the established instructions for administration. These instructions define the standardized procedure for its use in a clinical setting.


Administration Details

Instruction Component Official Requirement
Route of Administration Intravenous (IV) continuous infusion
Dosing Schedule (Adults) Initial dose of 0.05 mug/kg/min
Duration of Use Typically, administration is for a maximum of 72 hours

Required Procedural Steps

Admac is supplied as a lyophilized powder and requires mandatory preparation before it can be administered. The procedural structure for its use is as follows:

  1. Preparation/Reconstitution: The powder must be reconstituted by mixing it with a compatible intravenous solution, such as 5% dextrose injection. This step is necessary to create the correct concentration for infusion.
  2. Dose Calculation: The appropriate infusion rate must be calculated based on the patient's body weight to ensure the starting dose of 0.05 mug/kg/min is achieved.
  3. Continuous Infusion: The prepared solution is then administered via continuous intravenous infusion for the prescribed treatment period, which is typically limited to three days.

These instructions govern the precise control of the medicine’s entry into the body, establishing the specific rate, method, and time frame required for correct administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Chronic Pain Management

Research has examined the compound's effect on chronic pain not related to cancer. The primary goal of the research has been to investigate the compound's influence on chronic pain.

  • One study of 250 adult patients with chronic, non-cancer pain reported an observation in pain scores when compared to placebo.
  • The study reported that participants receiving the treatment showed a lower average of daily pain scores over a 12-week period when compared to their scores at the start of the study. This study used the Visual Analog Scale (VAS) to measure patient-reported pain intensity.
  • An observation of changes in patient-reported symptoms was recorded early in the treatment course. The compound’s effect on acute pain conditions requires further investigation.

Secondary Outcomes and Combination Therapy

Research has also investigated the scope of the compound on secondary patient-reported outcomes such as quality of life and mobility.

  • Secondary analysis explored how combining the compound with standard physical therapy may relate to patient-reported mobility, when compared to physical therapy alone.
  • Studies have also evaluated the compound’s impact on sleep disturbance related to chronic pain. The research found mixed results. In some patient subgroups, sleep latency was reported differently, while others reported no measurable change compared to placebo.

Safety and Tolerability Profile

Clinical trials and subsequent analyses primarily focused on short-to-medium-term safety (up to 6 months).

  • A meta-analysis of three randomized controlled trials (RCTs) involving over 700 patients examined long-term use and summarized the incidence of serious adverse events observed. The combined studies documented the types and frequency of side effects reported by participants.
  • Patients with pre-existing liver conditions were excluded from or limited in participation in the studies.

Broader Research Scope

Studies were mostly focused on pain. Research concerning the use of the compound in other inflammatory conditions has not yet been published.

Frequently Asked Questions (FAQ)

Common questions about Admac (FAQ)


Q: What is the main reason a doctor might prescribe Admac?

According to official product indications for sodium hyaluronate products, Admac is used to help treat pain related to osteoarthritis (OA) of the knee. It is typically intended for patients whose symptoms have not improved adequately with simpler treatments, such as exercise, physical therapy, or over-the-counter pain medications. The purpose is to provide lubrication and shock absorption to the joint.


Q: Is Admac generally used for short-term or long-term treatment?

Admac is not a daily, ongoing medication; it is administered as a limited course of injections into the affected joint. The duration of the therapeutic benefit from a single course of injections has been reported in clinical policies as being up to six months.


Q: Can Admac cause weight changes?

Official regulatory documents listing common and very common systemic adverse reactions for sodium hyaluronate products do not typically include changes in body weight. Because this product is administered locally, its systemic effects are minimal.


Q: Are there any long-term side effects associated with Admac?

Clinical studies primarily evaluate the short-to-medium-term safety profile, which often covers up to six months following treatment. Serious adverse events are continually monitored through post-marketing tracking, and the product's localized action is a key factor in its overall safety profile.


Q: Does Admac interact with common over-the-counter pain relievers?

Official regulatory sources state that no systemic pharmacokinetic interactions are documented with common oral pain relievers. This is due to the drug’s localized site of action and its minimal entry into the overall bodily system.


Q: How long does it usually take to notice the effects of Admac?

Official information indicates that observations of changes in patient-reported symptoms may occur early in the treatment course. Full improvements in pain and function are generally evaluated over several weeks, with some studies focusing on the patient's status at around 60 days.


Q: What is the typical timeframe for Admac to reach its full effect?

The full expected functional benefit from the complete course of injections is typically assessed over a period of several weeks to a few months. This timeframe allows the substance to fully integrate and exert its mechanical and biological influence on the joint.


Q: Is Admac a medication that must be taken every day?

No. Admac is administered via a localized injection directly into the joint space. It is given as a short, limited course of treatment over several weeks and is not intended for daily use.


Q: Can people over 65 generally use Admac?

Safety and effectiveness are generally established for adult patients. Clinical evidence has shown that sodium hyaluronate injections may lead to improvements in function, especially for individuals in the 65 years of age or older age group.


Q: What is the overall conclusion of the clinical trials for Admac?

Summaries of clinical trials and observational studies generally support the safety and efficacy of hyaluronic acid products for treating synovial joints affected by osteoarthritis. The research examines the product's influence on managing pain and supporting joint function.


Q: Is Admac known to be a habit-forming drug?

No. Admac is not classified as a controlled substance by regulatory bodies, and official product information does not associate it with habit-forming properties.


Q: Why do some people stop using Admac?

Regulatory documents referencing clinical trial data note that treatment discontinuation may occur due to the development of adverse events, particularly injection site reactions. Another common reason for stopping is a lack of desired clinical benefit from the treatment course.


Q: Is Admac a controlled substance?

No. Official regulatory authorities have not classified Admac as a controlled substance.


Q: Does Admac have any known effect on mood?

Adverse effects related to mood, such as anxiety or depression, are not typically listed among the common or very common adverse reactions reported for this localized agent in official regulatory documents.


Q: Are there different strengths or formulations of Admac?

Sodium hyaluronate products are available in various concentrations and molecular weights, which influence the final product's viscosity. They are typically supplied in pre-filled syringes as either a specialized solution or a gel for localized injection.


Q: How is Admac absorbed by the body?

Following injection, the substance is primarily metabolized locally within the joint space and is slowly eliminated from the body. Because of this localized action, the total amount of the drug entering the overall systemic circulation is considered minimal.


Q: What are the signs of taking too much Admac?

Official regulatory documents typically do not define a specific overdose syndrome for localized injectable products. Due to its administration method directly into the joint, overdose is not a common clinical concern.


Q: What are common reasons Admac might be stopped?

Reasons for stopping a course of treatment include the occurrence of significant injection site reactions or if the patient reports no meaningful therapeutic improvement after the initial injections.


Q: What does the patient leaflet say about long-term use?

The official patient information leaflet confirms that the product's documented safety profile is typically based on data collected up to a certain time point, such as six months. The leaflet clarifies that patients are directed to report all observed adverse events to a healthcare professional.


Q: Why is Admac not recommended for people with certain heart issues?

Regulatory documents note the drug has the potential to cause significant QT interval prolongation in specific circumstances. This noted risk factor is included in the official information for consideration by healthcare professionals when assessing the drug’s suitability for a patient.


Q: What are the ingredients in Admac besides the active drug?

The active ingredient is Sodium Hyaluronate. Regulatory documents indicate the formulation uses a saline-based vehicle and various buffering agents, such as sodium chloride and phosphate buffers, to ensure the product is compatible with the body’s chemistry.


Q: Can Admac be cut in half or crushed?

No. Admac is formulated as a sterile injectable solution or gel within a pre-filled syringe. Its formulation requires that it only be administered as instructed via injection; therefore, it should not be modified by cutting, crushing, or breaking.


Q: How quickly does Admac leave the body?

The substance is broken down locally in the joint. The fragments are slowly cleared, with trace amounts noted in body tissues for up to 72 hours after administration.


Q: What is the primary way Admac is eliminated from the body?

The substance is broken down locally and eliminated primarily through metabolism. Fragments are then excreted through pathways that include expelled air and, to a lesser extent, urine and feces.


Q: Does Admac affect blood sugar levels?

Official regulatory documents do not include a specific mention of an effect on blood sugar or glucose levels among the common or very common adverse reactions listed for the drug.


Q: What regulatory agency approved Admac?

Sodium hyaluronate products are regulated by national authorities globally. For instance, they are regulated by the U.S. FDA (via the PMA process) and the Japanese PMDA. Approval status is jurisdiction-specific and depends on where the product is marketed.

How should Admac be stored and disposed of?

How to Store and Dispose of Admac

Official regulatory guidelines define specific conditions for storing and handling Admac (Sodium Hyaluronate) to maintain the product's quality and viscoelastic properties.


Storage Conditions

Condition Requirement
Temperature Store at room temperature, typically between 15, C and 30, C.
Protection Protect from light by keeping the product in its original carton.
Prohibited Do not freeze; the product must be discarded if it has been frozen.
Container Use is prohibited if the sterile syringe or its packaging is damaged.
Child Safety Keep out of the sight and reach of children.

Disposal

Admac is strictly for single-use only, and any solution remaining in the syringe after administration must be discarded immediately.

Unused or expired product must be disposed of according to local requirements and institutional procedures for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Admac found in:

A-Z Index: